GlaxoSmithKline set to standardise on Autonomy platform

GlaxoSmithKline (GSK) is to standardise on an information processing platform from Autonomy to enable it to begin automating more of its information processing operations.

GlaxoSmithKline (GSK) is to standardise on an information processing platform from Autonomy to enable it to begin automating more of its information processing operations.

The pharmaceutical giant is globally implementing Autonomy’s IDOL 7 platform.

“It was essential for us to select an infrastructure that could integrate all of our data regardless of format and maintain performance,” said Ingo Elfering, vice-president of GSK global application services.

“The decision to deploy Autonomy to underpin and automate a wide spectrum of information processing operations globally enables the company to minimise the costs and risks of transacting real-time digital information while simultaneously maximising its value,” said Elfering.

Mike Lynch, CEO of Autonomy, said, “I am delighted that GSK has selected Autonomy after a competitive procurement, bringing the benefits of Idol 7 to hundreds of thousands of users around the globe.

Glaxo boost analytics with Spotfire

GlaxoSmithKline saves more than £1bn with e-sourcing

Comment on this article: computer.weekly@rbi.co.uk

CW+

Features

Enjoy the benefits of CW+ membership, learn more and join.

Read more on Business applications

Start the conversation

Send me notifications when other members comment.

By submitting you agree to receive email from TechTarget and its partners. If you reside outside of the United States, you consent to having your personal data transferred to and processed in the United States. Privacy

Please create a username to comment.

-ADS BY GOOGLE

SearchCIO

SearchSecurity

SearchNetworking

SearchDataCenter

SearchDataManagement

Close